GLP-1s Move Beyond Weight Loss: Parkinson's, Kidneys, Eyes, and the Brain

The most consequential trial of the year for this thesis is also the one that, on its face, delivered the most ambiguous result. Investigators ran a phase 3, multicentre, double-blind, randomised, placebo-controlled trial across six UK research hospitals, assigning people with early Parkinson's disease to either extended-release exenatide 2 mg once weekly or a visually identical placebo for 96 weeks. The primary outcome was the MDS-UPDRS Part III motor score, measured off dopaminergic medication at the two-year mark — a deliberately demanding endpoint, because it tries to read the underlying disease through the noise of symptomatic therapy.

The rationale was not speculative. GLP-1 receptor agonists have neurotrophic effects in cellular and animal models of Parkinson's, and earlier small randomised trials and epidemiology had hinted at slower progression in treated patients. A properly powered phase 3 in a neurodegenerative disease is, in itself, a milestone for this class. Whether exenatide bends the trajectory of Parkinson's is a question the field has been waiting a decade to ask seriously; the trial provides the first rigorous, well-controlled answer at scale.

If the Parkinson's story is high-risk, high-reward, the kidney story is closer to consolidation. A 2025 systematic review and meta-analysis in the American Journal of Kidney Diseases pooled 12 randomised trials enrolling 17,996 participants whose baseline estimated glomerular filtration rate was below 60 mL/min/1.73m² — the threshold defining chronic kidney disease. Across those trials, GLP-1 receptor agonists were associated with improvements in a composite kidney outcome and in cardiovascular endpoints, in a population that historically has been under-represented in cardiometabolic research and harder to treat safely.

That matters for two reasons. First, CKD and cardiovascular disease are so tightly coupled that a drug class which moves both needles in the same direction is genuinely useful. Second, much of the GLP-1 conversation has implicitly assumed an otherwise healthy patient losing weight; this evidence speaks to people with established organ disease, where the risk-benefit math is different and the stakes are higher.

The ocular signal is the most surprising of the new findings, and the one to read with the most caution. A retrospective cohort study published in Ophthalmology drew on a U.S. electronic health records platform, restricting to patients over 60 with at least five years of ophthalmology follow-up. Propensity-matched against users of metformin, insulin, and statins, GLP-1 receptor agonist users showed a reduced hazard of non-exudative age-related macular degeneration: hazard ratios of 0.68 versus metformin, 0.72 versus insulin, and 0.70 versus statins, each statistically significant.

This is a retrospective design, not a randomised trial, and 84% of the GLP-1 cohort had diabetes — a population whose ocular risk profile differs from the general public. Residual confounding is unavoidable. But the direction and consistency of the effect across multiple comparator groups is the kind of signal that, in any other organ system, would launch a prospective study. It probably will here, too.

The mechanistic case is where the futurist in me has to slow down. A recent review in The American Journal of Medicine maps the central and peripheral pathways through which GLP-1 receptor agonists drive weight loss: they modulate appetite circuits in the brain, enhance insulin secretion and suppress glucagon, delay gastric emptying, reduce triglycerides and LDL cholesterol, dampen adipose tissue inflammation, and limit ectopic fat. The same review notes the rise of dual and triple co-agonists targeting GLP-1 alongside glucose-dependent insulinotropic polypeptide and glucagon — a pharmacological direction that is already in late-stage development.

Several of those mechanisms — anti-inflammatory effects on the vasculature, modulation of neuronal energy metabolism, improvements in lipid handling — are plausible upstream causes of benefit in kidneys, retina, and brain. That does not prove the connection. It does mean the cross-organ pattern is biologically coherent rather than coincidental, which is the minimum bar for taking a hypothesis seriously.

Earlier-stage work is also feeding the pipeline. A preclinical study in a zebrafish model of high-fat-diet-induced type 2 diabetes reported that tirzepatide, a dual GIP/GLP-1 agonist, mitigated cognitive decline on behavioural tests and improved antioxidant and anti-inflammatory markers. Zebrafish are zebrafish — this is hypothesis-generating, nothing more — but it is the kind of preclinical signal that, combined with human data in adjacent indications, makes a research program rather than an anecdote.

The honest synthesis is that GLP-1 receptor agonists are graduating from a metabolic drug class into something more interesting — a candidate platform for multi-system intervention in aging-related disease. The evidence is moderate, not definitive: one phase 3 in neurodegeneration, one strong meta-analysis in kidney disease, one observational cohort in ophthalmology, and a coherent mechanistic story tying them together. That is exactly the stage at which a careful reader pays attention and a cautious patient waits for the next round of data.

The next eighteen months should clarify a great deal: longer follow-up in CKD, prospective ocular studies, replication of the Parkinson's signal in other neurodegenerative endpoints, and head-to-head data on the dual and triple agonists already in trials. For now, the right posture is the one this magazine tries to take consistently — intellectually excited, disciplined about the caveats, and unwilling to confuse a promising signal with a settled result.